Type III Interferons IL-28 and IL-29: Novel Interferon Family Members with Therapeutic Potential in Cancer Therapy

Fujie, Hiromi; Numasaki, Muneo

doi:10.5772/28436

Cited by 2 publications

(1 citation statement)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While these three cytokines are usually described in unison under the IFN title, there are differences that distinguish IL-29 from IL28A and IL28B. Both IL-28A and IL28B are nearly structurally identical to each other, while IL-29 is more structurally unique (Fujie and Numasaki, 2012). IL-29 is the most potent IFN molecule in humans, as well as the most abundant IFN molecule in serum, despite only existing as a pseudogene in mice (Donnelly and Kotenko, 2010;Alborzi et al, 2015;Hamming et al, 2010;Lasfar et al, 2006;Maher et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

The role of IL-29 in immunity and cancer

Kelm

Zhu

Ding

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Interleukin-29 (IL-29) is a new member of the recently discovered interferon λ (IFNλ) family. It is produced predominantly by maturing dendritic cells and macrophages. It has been implicated in numerous immunological responses and has shown antiviral activity similar to the Type I interferons, although its target cell population is more limited than the Type I interferons. In recent years, the role of IL-29 in the pathogenesis of various cancers has also been extensively studied. In this review, we will discuss the recent advances of IL-29 in immunological processes and the pathogenesis of various cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

The role of IL-29 in immunity and cancer

Kelm

Zhu

Ding

et al. 2016

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

show abstract

In vitro and computational studies on the effects of ARE deletion and targeted mutations on the expression of interferon beta-1a in HEK293T cells

Norouzi

Hojati

Dehbashi

2018

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Interferon beta (IFNβ) is transiently expressed in response to viral infections and widely used to treat relapsing-remitting multiple sclerosis (MS). We introduced mutations in the IFNβ gene (in the 27th and 101st codons and in the Kozak sequence, and also deletion of 3' and 5' unstable, untranslated region, UTR) with the aim of increasing the expression of IFNβ. Computational analyses of mutant and wild-type RNAs and proteins of IFNβ by RNAfold, ASAView, HOPE and Ramachandran plot, and iStable web servers showed that the mutations could decrease RNA stability, protein solvent accessibility, and protein stability but could not change correct folding. Two recombinant IFNβ101 and IFNβ101+27 constructs were designed by site-directed mutagenesis. The wild-type IFNβ gene also was used as a control. In vitro experiments by quantitative real-time PCR, dot blot, SDS-PAGE, and Western blot assays showed an increased expression level of recombinant IFNβs. 79.9-fold, 99.7-fold, and 190-fold elevations in the mRNA expression of IFNβw, IFNβ101, and IFNβ101+27 were seen, respectively, in comparison with the endogenous IFNβ mRNA in untransfected HEK293T cells. The IFNβ mRNA expression was increased 2.38-fold and 1.25-fold for 101+27 and 101 mutated forms, respectively, in comparison with the IFNβ wild-type construct. An elevation in IFNβ protein production was also clearly detected in the transfected HEK293T cell containing recombinant IFNβ101 and IFNβ101+27 constructs. Finally, these directed mutations in the IFNβ gene successfully elevated protein and mRNA production but in silico analyses of mutant mRNAs showed decreased mRNA stability, unlike previous studies, in comparison with the wild-type mRNA.

show abstract

Type III Interferons IL-28 and IL-29: Novel Interferon Family Members with Therapeutic Potential in Cancer Therapy

Cited by 2 publications

References 89 publications

The role of IL-29 in immunity and cancer

The role of IL-29 in immunity and cancer

In vitro and computational studies on the effects of ARE deletion and targeted mutations on the expression of interferon beta-1a in HEK293T cells

Contact Info

Product

Resources

About